News

Subcutaneous zilucoplan –⁠ the end of necessary “trips” to the hospital for myasthenia gravis patients?

3. 4. 2024 Source: Rare Diseases in Neurology

A study recently published in Lancet Neurology demonstrated the efficacy and safety of the subcutaneously administered complement component C5 inhibitor –⁠ zilucoplan –⁠ in the treatment of myasthenia gravis (MG). This drug has the potential to alleviate the severity of this disease and improve the quality of life of patients.

Wireless Smart Devices Monitor Health by Detecting Sounds

The human body continuously emits various forms of acoustic-mechanical signals that can provide important information about its health. Researchers from Northwestern University in the USA have…

2. 4. 2024 Source:

Economic Burden and Loss of Quality of Life as a Consequence of Dry Eye Syndrome

Canadian authors evaluated the direct and indirect financial costs associated with dry eye syndrome (DED −⁠ dry eye disease) and the impact of this condition on the quality of life (QoL) of patients.…

1. 4. 2024 Source: Treatment of Glaucoma

INFOGRAPHIC: Beneficial Effect of Preservative-Free Drops on the Eye Surface of Patients with Open-Angle Glaucoma

31. 3. 2024 Source: Treatment of Glaucoma

Advances in the Treatment of Myasthenia Gravis on the Horizon

The research of new drugs for the generalized form of myasthenia gravis has made significant progress in recent years. How is the new specific therapy performing? And are we heading towards a radical…

28. 3. 2024 Source: Rare Diseases in Neurology

Biocompatibility of 3D Printed Materials –⁠ Their Comparison, Legislation, and Practice

Printing three-dimensional (3D) objects brings new possibilities for producing personalized implants, prosthetics, and other medical devices in healthcare. One area where this technology can improve…

27. 3. 2024 Source:

Pegylated Liposomal Irinotecan + 5-FU/LV in the Treatment of mPDAC in Czech Clinical Practice –⁠ Results from the VILP Registry

At last year's annual congress of the European Society for Medical Oncology (ESMO) and this year's 15th PragueONCO, results from the Czech VILP registry were presented. This registry collected data…

25. 3. 2024 Source: Treatment of Gastrointestinal Carcinomas

Bimekizumab in 3rd Line Biological Treatment After Risankizumab Failure –⁠ Case Study

The possibilities of biological therapy for severe forms of psoriasis are very broad today. Achieving remission or reducing disease activity by 90-100% from the baseline state (PASI 90-100) is highly...

22. 3. 2024 Source: Psoriasis

How Does Artificial Intelligence Help in Drug Development?

In recent years, technologies leveraging artificial intelligence have transitioned from potentially interesting novelties to real clinical development programs. What can artificial intelligence offer…

20. 3. 2024 Source:

Improvement in social functioning of patients with schizophrenia during treatment with lurasidone

A beneficial impact on social functioning is an important outcome of schizophrenia treatment. A recently published Japanese study is the first to demonstrate the efficacy of lurasidone compared to…

19. 3. 2024 Source: Modern Treatment of Schizophrenia

What to add to amlodipine when it alone is not enough for hypertension?

Treating hypertension is a daily task for not only general practitioners and cardiologists. Polish doctors evaluated the effect of adding bisoprolol on the blood pressure of patients with…

18. 3. 2024 Source: Cardiovascular Continuum

Effect of Extended-Release Metformin on Cognitive Functions in Older Frail Women with Diabetes and Hypertension

Women have a higher risk of geriatric frailty regardless of age and menopausal status. This risk further increases with the presence of diabetes and hypertension, which also elevate the risk of…

14. 3. 2024 Source: Cardiovascular Risks

ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK

Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and prevalence of HF with preserved left ventricular ejection fraction (HFpEF) rising. The following…

14. 3. 2024 Source: Heart Failure

Causes, Consequences, and Solutions to Weight Gain in Schizophrenia Treatment

The use of antipsychotics in the treatment of schizophrenia is often associated with the development of overweight and obesity, which poses a risk for the onset of many diseases and increases…

13. 3. 2024 Source: Modern Treatment of Schizophrenia

Current findings on the treatment of gestational diabetes and DM2 in pregnancy with metformin

Recent reviews have shown that metformin is a safe alternative to insulin in the treatment of diabetes during pregnancy. For gestational diabetes (GDM) and type 2 diabetes mellitus (DM2), metformin…

12. 3. 2024 Source: Modern Treatment of Diabetes

1 … 13 14 15 16 17 … 115

Back Filter by speciality

Remove filters

Popular this week